Bayer IR Newsfeed: Events

27.01.12: Milestone for stacked insect-resistant, herbicide-tolerant cotton

ir@bayer.com — Fri, 27 Jan 2012 13:00:04 +0100

Bayer CropScience's TwinLink� cotton technology receives full authorization in the US

mehr ...

18.01.12: Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:

ir@bayer.com — Wed, 18 Jan 2012 07:00:04 +0100

Bayer's Xarelto� Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation

mehr ...

18.01.12: Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:

ir@bayer.com — Tue, 17 Jan 2012 23:00:04 +0100

Positive Phase III Data on Bayer's Investigational Drug Regorafenib Show Significant Increase in Overall Survival

First presentation of data from CORRECT trial as "Late Breaking Abstract" at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI)

mehr ...

10.01.12: Not intended for US Media: Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI):

ir@bayer.com — Tue, 10 Jan 2012 09:05:05 +0100

Phase III Data of Bayer's Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress

Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012

mehr ...

29.12.11: Not intended for U.S. and UK Media - Submission in New Indication:

ir@bayer.com — Thu, 29 Dec 2011 14:05:03 +0100

Bayer's Xarelto� (Rivaroxaban) Submitted for U.S. Marketing Authorisation to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

mehr ...

22.12.11: Not intended for U.S. and UK media: Acute Coronary Syndrome (ACS):

ir@bayer.com — Thu, 22 Dec 2011 10:55:03 +0100

Bayer's Xarelto� (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome

Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination with standard antiplatelet therapy

mehr ...

20.12.11: Bayer: Four potential blockbusters in the Pharma pipeline

ir@bayer.com — Tue, 20 Dec 2011 11:05:02 +0100

Bayer: Four potential blockbusters in the Pharma pipeline

Good prospects for Xarelto

mehr ...

19.12.11: For use outside the US and UK only

ir@bayer.com — Mon, 19 Dec 2011 13:10:04 +0100

Bayer's Xarelto� Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT

In stroke prevention in AF, Xarelto is the only oral anticoagulant offering patients a once-daily, highly effective therapy without need for routine coagulation monitoring / For the treatment of DVT and the prevention of recurrent DVT and PE, Xarelto is the first oral anticoagulant to offer patients both efficacy and the convenience of a single-drug solution, without the need for injections or monitoring / Xarelto is now approved in the EU across three indications in the area of venous and arterial thromboembolism (VAT)

mehr ...

15.12.11: Settlement agreements with U.S. long-grain rice growers have taken effect

ir@bayer.com — Thu, 15 Dec 2011 17:40:05 +0100

Settlement agreements with U.S. long-grain rice growers have taken effect

mehr ...

14.12.11: For use outside the US and UK only

ir@bayer.com — Wed, 14 Dec 2011 07:35:03 +0100

New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.

Once approved, the new low dose IUS will offer young women contraception for up to three years

mehr ...

09.12.11: Not intended for U.S. and UK media: Bayer's drospirenone-containing combination oral contraceptives:

ir@bayer.com — Fri, 9 Dec 2011 01:40:02 +0100

FDA Advisory Committees affirm positive benefit-risk profile and recommend an update of US labels to reflect information from available studies

mehr ...

06.12.11: Company streamlines its crop protection portfolio further:

ir@bayer.com — Tue, 6 Dec 2011 13:50:10 +0100

Bayer CropScience divests Rovral� and Sportak� fungicides to FMC

mehr ...

28.11.11: Not intended for U.S. and UK Media

ir@bayer.com — Mon, 28 Nov 2011 07:30:03 +0100

Bayer and Regeneron Initiate Phase III Clinical Trial for the Treatment of Wet Age-Related Macular Degeneration in China

mehr ...

16.11.11: "Perspective on Growth in Asia"

ir@bayer.com — Wed, 16 Nov 2011 05:35:03 +0100

Bayer plans further expansion in Asia

Sales in the region to grow to well over EUR 11 billion by 2015 / Some EUR 6 billion in sales expected in Greater China alone / Plans to expand production, distribution network and research / Further capital expenditures of EUR 1.8 billion in Asia by 2015 / New TDI production facility dedicated in Shanghai

mehr ...

13.11.11: Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):

ir@bayer.com — Sun, 13 Nov 2011 16:20:04 +0100

Bayer's Xarelto� (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study

Rivaroxaban Meets Primary Efficacy Endpoint, Significantly Reducing the Composite of Cardiovascular Death, Myocardial Infarction and Stroke / Rivaroxaban 2.5 mg twice daily Significantly Reduced Both the Rate of Cardiovascular Death and the Incidence of All-Cause Mortality by more than 30% / Major Bleeding in Patients Receiving Rivaroxaban was Significantly Increased but there was no Increase in the Risk of Fatal Bleeding / Study Results Presented as a Late-Breaker at the Scientific Sessions of the American Heart Association and Published by the New England Journal of Medicine

mehr ...